Leerink Partners analyst Roanna Ruiz has reiterated their bullish stance on SCPH stock, giving a Buy rating on August 8.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Roanna Ruiz’s rating is based on scPharmaceuticals’ impressive financial performance and strategic advancements. The company reported a significant year-over-year revenue growth of 99% in the second quarter of 2025, driven primarily by its cardiology sector, with promising early results in nephrology. The rapid adoption by nephrologists and the expansion to approximately 4,700 unique prescribers indicate a strong market presence.
Additionally, scPharmaceuticals is benefiting from favorable Medicare Part D dynamics, which are improving patient access and prescription fill rates. The company’s IDN business is also showing robust growth, contributing substantially to total sales. Furthermore, the upcoming sNDA submission for the autoinjector program is expected to enhance market penetration by significantly reducing costs and treatment times. These factors, combined with a solid cash position and strategic focus on profitability, underpin the Buy rating.
In another report released on August 8, Craig-Hallum also reiterated a Buy rating on the stock with a $12.00 price target.